ALKS Alkermes plc
Price (delayed)
$31.3
Market cap
$5.06B
P/E Ratio
15.57
Dividend/share
N/A
EPS
$2.01
Enterprise value
$5.03B
Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by
Highlights
The EPS has soared by 56% year-on-year and by 16% since the previous quarter
Alkermes's net income has soared by 55% YoY and by 15% from the previous quarter
ALKS's P/E is 22% above its last 4 quarters average of 12.8
Alkermes's gross profit has decreased by 8% YoY
Key stats
What are the main financial stats of ALKS
Market
Valuations
Earnings
Shares outstanding
161.8M
Market cap
$5.06B
Enterprise value
$5.03B
Price to earnings (P/E)
15.57
Price to book (P/B)
3.99
Price to sales (P/S)
3.4
EV/EBIT
16.19
EV/EBITDA
14.34
EV/Sales
3.34
Revenue
$1.51B
Gross profit
$1.25B
Operating income
$436.52M
Net income
$333.35M
EBIT
$310.87M
EBITDA
$351.1M
Free cash flow
$413.96M
Per share
Balance sheet
Liquidity
EPS
$2.01
EPS diluted
$1.97
Free cash flow per share
$2.53
Book value per share
$7.85
Revenue per share
$9.21
TBVPS
$12.68
Total assets
$2.16B
Total liabilities
$863.19M
Debt
$366M
Equity
$1.29B
Working capital
$1.11B
Debt to equity
0.28
Current ratio
3.45
Quick ratio
2.81
Net debt/EBITDA
-0.09
Margins
Efficiency
Dividend
EBITDA margin
23.3%
Gross margin
83.2%
Net margin
22.1%
Operating margin
29%
Return on assets
15.5%
Return on equity
26.5%
Return on invested capital
20.7%
Return on capital employed
18.3%
Return on sales
20.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALKS stock price
How has the Alkermes stock price performed over time
Intraday
1.76%
1 week
0.16%
1 month
7.78%
1 year
17.05%
YTD
8.83%
QTD
8.83%
Financial performance
How have Alkermes's revenue and profit performed over time
Revenue
$1.51B
Gross profit
$1.25B
Operating income
$436.52M
Net income
$333.35M
Gross margin
83.2%
Net margin
22.1%
The net margin has soared by 64% YoY and by 16% from the previous quarter
Alkermes's net income has soared by 55% YoY and by 15% from the previous quarter
Alkermes's operating income has decreased by 8% YoY but it has increased by 3.7% from the previous quarter
Alkermes's gross profit has decreased by 8% YoY
Growth
What is Alkermes's growth rate over time
Valuation
What is Alkermes stock price valuation
P/E
15.57
P/B
3.99
P/S
3.4
EV/EBIT
16.19
EV/EBITDA
14.34
EV/Sales
3.34
The EPS has soared by 56% year-on-year and by 16% since the previous quarter
ALKS's P/E is 22% above its last 4 quarters average of 12.8
The P/B is 14% higher than the 5-year quarterly average of 3.5 and 11% higher than the last 4 quarters average of 3.6
The company's equity fell by 4.7% YoY
ALKS's P/S is 21% above its last 4 quarters average of 2.8 and 6% above its 5-year quarterly average of 3.2
The revenue has contracted by 5% YoY
Efficiency
How efficient is Alkermes business performance
The ROA has soared by 50% YoY and by 17% QoQ
The return on equity has increased by 45% year-on-year and by 17% since the previous quarter
The ROS is up by 27% year-on-year and by 25% since the previous quarter
The ROIC has increased by 20% from the previous quarter and by 11% YoY
Dividends
What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALKS.
Financial health
How did Alkermes financials performed over time
Alkermes's total assets is 150% higher than its total liabilities
The current ratio has grown by 19% YoY and by 15% from the previous quarter
ALKS's quick ratio is up by 17% since the previous quarter and by 15% year-on-year
The debt is 72% less than the equity
The debt has contracted by 4.9% YoY
The company's equity fell by 4.7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.